Drugs for Gastrointestinal Diseases Practice Questions

Q: A 55-year-old woman is undergoing chemotherapy for breast cancer and experiences severe nausea and vomiting. Which antiemetic, recognized for its minimal extrapyramidal side effects, would be appropriate for her condition?

Ondansetron. ***Ondansetron*** - **Ondansetron** is a 5-HT3 receptor antagonist, highly effective against chemotherapy-induced nausea and vomiting (CINV) due to its action on serotonin receptors in the **chemoreceptor trigger zone** and **gastrointestinal tract**. - It is known for its favorable side effect profile, with **minimal to no extrapyramidal symptoms**, making it a preferred choice in patients where such effects are a concern. *Metoclopramide* - While effective against nausea and vomiting, **metoclopramide** (a D2 receptor antagonist) can cause **extrapyramidal symptoms** such as **dystonia** and **tardive dyskinesia**, especially with prolonged use or higher doses. - Its mechanism of action includes both prokinetic effects and central antiemetic action, but its side effect profile makes it less ideal when avoiding extrapyramidal symptoms is a priority. *Promethazine* - **Promethazine** is a first-generation antihistamine with antiemetic properties, but it can cause significant **sedation** and has some **anticholinergic side effects**. - Although its extrapyramidal risk is lower than some other drugs, it's not the primary choice for chemotherapy-induced nausea due to its sedative effects and generally less potent antiemetic action for CINV compared to 5-HT3 antagonists. *Prochlorperazine* - **Prochlorperazine** is a phenothiazine antipsychotic with strong antiemetic effects, acting primarily as a **dopamine receptor antagonist**. - It carries a significant risk of **extrapyramidal side effects**, including **acute dystonia** and **parkinsonism**, making it less suitable when such side effects must be strictly avoided.

Q: Which of the following is not a prokinetic agent?

Atropine. **Atropine** - **Atropine** is an **anticholinergic agent** that blocks muscarinic acetylcholine receptors, leading to decreased gastrointestinal motility. - Prokinetic agents, in contrast, **enhance gastrointestinal motility**; therefore, atropine is not a prokinetic. *Dopamine antagonist* - **Dopamine D2 receptor antagonists** (e.g., metoclopramide, domperidone) are prokinetic agents because dopamine normally inhibits acetylcholine release in the gut. - By blocking dopamine's inhibitory action, these agents **promote acetylcholine release**, thereby increasing gastrointestinal motility. *5HT4 agonist* - **5-HT4 receptor agonists** (e.g., cisapride, prucalopride) stimulate acetylcholine release in the enteric nervous system. - This results in **enhanced gastrointestinal contractions** and accelerated transit, classifying them as prokinetic agents. *Macrolides* - Certain **macrolide antibiotics** (e.g., erythromycin) act as **motilin receptor agonists**. - Motilin is a hormone that **stimulates smooth muscle contraction** in the stomach and small intestine, making macrolides effective prokinetic agents.

Q: MOA of Teduglutide in short bowel syndrome?

GLP-2 analog. ***GLP-2 analog*** - Teduglutide is a **glucagon-like peptide-2 (GLP-2) analog** that binds to and activates GLP-2 receptors. - This activation promotes **intestinal adaptation** by enhancing mucosal growth, increasing nutrient absorption, and improving fluid balance in patients with short bowel syndrome. *5-HT1A receptor antagonist* - 5-HT1A receptor antagonists are primarily used in conditions related to **serotonin pathways**, such as anxiety or depression. - They do not have a direct mechanism to address the **malabsorption** issues seen in short bowel syndrome. *GLP-1 receptor agonist* - GLP-1 receptor agonists are primarily used in the management of **type 2 diabetes** to enhance insulin secretion and reduce glucagon levels. - While GLP-1 and GLP-2 are related, GLP-1 does not have the same direct **trophic and restorative effects** on the intestinal mucosa as GLP-2. *C-peptide analog* - C-peptide is a byproduct of **insulin production** and its analogs have been studied for potential effects on diabetic neuropathy or nephropathy, but not for intestinal adaptation. - It does not play a direct role in regulating **intestinal growth** or nutrient absorption in the context of short bowel syndrome.

Q: What is the mechanism of action of aprepitant?

NK 1 receptor antagonist. ***NK 1 receptor antagonist*** - Aprepitant selectively blocks the **neurokinin-1 (NK1) receptor**, which is activated by **substance P**. - This mechanism is effective in preventing both acute and delayed **chemotherapy-induced nausea and vomiting (CINV)** by inhibiting the CNS vomiting reflex. *RANK ligand inhibitor* - **RANK ligand inhibitors** such as **denosumab** target bone resorption in conditions like osteoporosis and bone metastases. - This mechanism is not related to the antiemetic properties of aprepitant. *NMDA antagonist* - **NMDA receptor antagonists** like **ketamine** are primarily used for their anesthetic or analgesic effects. - They work by blocking the N-methyl-D-aspartate receptor, which is distinct from the NK1 receptor. *5-HT3 antagonist* - **5-HT3 antagonists** like **ondansetron** block serotonin receptors, primarily in the gastrointestinal tract and chemoreceptor trigger zone. - While also antiemetics, their mechanism is different from aprepitant, and they are often used in combination for CINV.

Q: Which is the most potent H2 antagonist?

Famotidine. ***Famotidine*** - Famotidine is considered the **most potent H2 antagonist**, demonstrating a significantly **higher affinity** for the H2 receptor compared to other drugs in its class. - Its high potency allows for **effective acid suppression** at lower doses. *Ranitidine* - Ranitidine is a potent H2 antagonist, but it is **less potent than famotidine**. - It has been a widely used H2 blocker but is now less favored due to concerns about **NDMA contamination**. *Cimetidine* - Cimetidine was the **first H2 antagonist** introduced but is the **least potent** among the options listed. - It is associated with more drug interactions and side effects due to its inhibition of **cytochrome P450 enzymes**. *Nizatidine* - Nizatidine has a **similar potency to ranitidine**, making it less potent than famotidine. - It has a unique characteristic of being **primarily eliminated by the kidneys (excreted unchanged in urine)**.

Q: Which of the following is not an adverse effect of cimetidine?

Decreased prolactin levels. ***Decreased prolactin levels*** - Cimetidine, an **H2 receptor antagonist**, is known to **increase prolactin levels** due to its anti-androgenic effects and effects on dopamine regulation, not decrease them. - This elevation in prolactin can lead to side effects such as **galactorrhea** and **gynecomastia**. *Confusional state, restlessness* - Cimetidine can cross the **blood-brain barrier** and block H2 receptors in the central nervous system, leading to **CNS side effects** like confusion, disorientation, agitation, and hallucinations, especially in elderly patients or those with renal impairment. - These effects are less common with newer H2 blockers that have lower CNS penetration. *Gynecomastia* - Cimetidine has **anti-androgenic effects** by binding to androgen receptors and inhibiting the metabolism of estrogens, which can lead to an increase in estrogen-to-androgen ratio. - This imbalance can result in increased breast tissue development in males, known as **gynecomastia**, and also **sexual dysfunction**. *Dry mouth* - Dry mouth is **not a recognized adverse effect** of cimetidine, as H2 receptor antagonists do not possess anticholinergic properties [1]. - Unlike anticholinergic drugs that block muscarinic receptors [1], cimetidine specifically blocks histamine H2 receptors and does not interfere with salivary secretion. - This option may serve as a distractor, as dry mouth is commonly associated with other drug classes but not with H2 blockers [1].

Q: Racecadotril is primarily used for which type of diarrhea?

Acute secretory diarrhea. ***Acute secretory diarrhea*** - **Racecadotril** is an **opioid-based antidiarrheal drug** that acts as an **enkephalinase inhibitor**. - It reduces the secretion of water and electrolytes into the intestine by inhibiting the degradation of **endogenous enkephalins**, which then bind to **delta-opioid receptors** on enterocytes, making it effective for secretory diarrhea. *Chronic diarrhea* - While racecadotril can reduce the symptoms of diarrhea, it is not the primary treatment for **chronic diarrhea**, which often requires identifying and treating the underlying cause. - Chronic diarrhea can be caused by various factors like **malabsorption**, **inflammatory bowel disease**, or **irritable bowel syndrome**, which racecadotril does not address directly. *Chronic constipation* - **Chronic constipation** involves infrequent or difficult bowel movements, which is the opposite of diarrhea. - Racecadotril works by reducing fluid secretion into the bowel and has no role in treating constipation; it would likely worsen it if used. *Diabetic gastroparesis* - **Diabetic gastroparesis** is a condition where stomach emptying is delayed, leading to symptoms like **nausea**, **vomiting**, and **early satiety**. - It is a disorder of motility, not primarily a secretory disorder of the small or large intestine, and is usually managed with **prokinetic agents** like metoclopramide or erythromycin.

Q: The two molecules of Aminosalicylate coupled via azo bond form?

Olsalazine. ***Olsalazine*** - **Olsalazine** is formed by coupling two molecules of **5-aminosalicylate (5-ASA)** via an **azo bond**. - This design allows the drug to be cleaved by **bacterial azoreductases** in the colon, releasing active 5-ASA directly at the site of inflammation. *Mesalazine* - **Mesalazine** is the active compound **5-aminosalicylic acid (5-ASA)** itself, not a coupled dimer. - It is delivered to the colon via various formulations that protect it from absorption in the upper GI tract. *Balsalazine* - **Balsalazine** consists of **5-aminosalicylate (5-ASA)** linked to an inert carrier molecule (**4-aminobenzoyl-beta-alanine**) by an **azo bond**. - This linkage prevents early absorption and releases 5-ASA specifically in the colon. *Sulfasalazine* - **Sulfasalazine** is a prodrug composed of **sulfapyridine** and **5-aminosalicylate (5-ASA)** linked by an **azo bond**. - While it contains an azo bond, it involves 5-ASA and a sulfapyridine moiety, not two molecules of aminosalicylate.

Q: Erythromycin is used in the treatment of which GIT disorder?

Diabetic gastroparesis. ***Diabetic gastroparesis*** - Erythromycin acts as a **motilin receptor agonist**, mimicking the effect of motilin, a hormone that stimulates **gastric motility**. - This prokinetic effect helps to improve **gastric emptying** in patients with diabetic gastroparesis, who often experience delayed emptying due to autonomic neuropathy. *Bacillary dysentery* - This condition is typically caused by bacterial infections like **Shigella**, requiring antibiotics such as **fluoroquinolones** or **azithromycin**. - Erythromycin is not a primary treatment for bacillary dysentery due to its limited efficacy against the common causative organisms and potential for increased resistance. *Amoebic dysentery* - Caused by the parasite **Entamoeba histolytica**, treatment involves **amoebicidal agents** like **metronidazole** followed by a luminal agent such as paromomycin. - Erythromycin has no significant activity against amoebae and is therefore ineffective in treating amoebic dysentery. *Ulcerative colitis* - This is an **inflammatory bowel disease** characterized by chronic inflammation of the colon, managed with **anti-inflammatory drugs** (e.g., mesalamine, corticosteroids) and **immunomodulators**. - Erythromycin has no role in directly treating the inflammation of ulcerative colitis; antibiotics may be used in specific cases of infectious complications, but not as primary therapy for the disease itself.

Q: Which of the following is a Cl- channel activator related to gastrointestinal conditions?

Lubiprostone. **Lubiprostone** - Lubiprostone is a **prostanoid derivative** that specifically activates **chloride channels (ClC-2)** in the apical membrane of gastrointestinal epithelial cells [1]. - This activation leads to increased fluid secretion into the intestinal lumen, softening stool and promoting bowel movements, making it useful for treating **chronic idiopathic constipation (CIC)** and **irritable bowel syndrome with constipation (IBS-C)** [1]. *Nefazodone* - Nefazodone is an **antidepressant** that acts as a **serotonin 5-HT2 and alpha-1 adrenergic receptor antagonist**, and also inhibits serotonin and norepinephrine reuptake. - Its primary therapeutic use is in the treatment of **depression**, and it does not directly act as a chloride channel activator for gastrointestinal conditions. *Varenicline* - Varenicline is a **nicotinic acetylcholine receptor partial agonist** used primarily for **smoking cessation**. - It reduces cravings and withdrawal symptoms associated with nicotine addiction, with no direct action on chloride channels in the gastrointestinal tract. *Valethamate* - Valethamate is an **anticholinergic and antispasmodic agent** sometimes used to relieve smooth muscle spasms in the gastrointestinal or genitourinary tracts. - It works by blocking muscarinic receptors and does not directly activate chloride channels to promote fluid secretion.

Question 1

A 55-year-old woman is undergoing chemotherapy for breast cancer and experiences severe nausea and vomiting. Which antiemetic, recognized for its minimal extrapyramidal side effects, would be appropriate for her condition?

Accepted Answer

Ondansetron

Answer

Metoclopramide

Answer

Promethazine

Answer

Prochlorperazine

Question 2

Which of the following is not a prokinetic agent?

Accepted Answer

Atropine

Answer

5HT4 agonist

Answer

Dopamine antagonist

Answer

Macrolides

Question 3

MOA of Teduglutide in short bowel syndrome?

Accepted Answer

GLP-2 analog

Answer

5-HT1A receptor antagonist

Answer

GLP-1 receptor agonist

Answer

C-peptide analog

Question 4

What is the mechanism of action of aprepitant?

Accepted Answer

NK 1 receptor antagonist

Answer

RANK ligand inhibitor

Answer

NMDA antagonist

Answer

5-HT3 antagonist

Question 5

Which is the most potent H2 antagonist?

Accepted Answer

Famotidine

Answer

Ranitidine

Answer

Cimetidine

Answer

Nizatidine

Question 6

Which of the following is not an adverse effect of cimetidine?

Accepted Answer

Decreased prolactin levels

Answer

Gynecomastia

Answer

Dry mouth

Answer

Confusional state, restlessness

Question 7

Racecadotril is primarily used for which type of diarrhea?

Accepted Answer

Acute secretory diarrhea

Answer

Chronic diarrhea

Answer

Chronic constipation

Answer

Diabetic gastroparesis

Question 8

The two molecules of Aminosalicylate coupled via azo bond form?

Accepted Answer

Olsalazine

Answer

Mesalazine

Answer

Balsalazine

Answer

Sulfasalazine

Question 9

Erythromycin is used in the treatment of which GIT disorder?

Accepted Answer

Diabetic gastroparesis

Answer

Bacillary dysentery

Answer

Amoebic dysentery

Answer

Ulcerative colitis

Question 10

Which of the following is a Cl- channel activator related to gastrointestinal conditions?

Accepted Answer

Lubiprostone

Answer

Nefazodone

Answer

Valethamate

Answer

Varenicline

Drugs for Gastrointestinal Diseases — MCQs

Drugs for Gastrointestinal Diseases — MCQs

On this page

Practice by Chapter

Want unlimited practice?